Baseline characteristics of the HCV patients completing triple therapy.
- Christina Sølund (667326)
- Henrik Krarup (213503)
- Santseharay Ramirez (667327)
- Peter Thielsen (667328)
- Birgit T. Røge (667329)
- Suzanne Lunding (667330)
- Toke S. Barfod (667331)
- Lone G. Madsen (667332)
- Britta Tarp (667333)
- Peer B. Christensen (667334)
- Jan Gerstoft (67009)
- Alex L. Laursen (174811)
- Jens Bukh (162343)
- Nina Weis (213509)
Publication date
December 2014
DOIAbstract
<p>*1 patient was lost to follow-up at treatment week 16.</p><p>**One patient was infected with HCV genotype 1l.</p>+<p>No material available in DANHEP for IL-28B genotyping.</p>++<p>Upper Normal Level (50 U/L).</p><p>SOC; standard of care, SVR; sustained viral response, IDU; intravenous drug use.</p><p>Baseline characteristics of the HCV patients completing triple therapy.</p
Add to ORKG